FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Medtronics Hemostasis Agent Cleared for Upper GI

FDA clears a Medtronic 510(k) for its Nexpowder endoscopic hemostasis system.

latest-news-card-1
Human Drugs

Amylyx Lou Gehrigs Disease Drug Approved

FDA approves Amylyxs amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig's disease) drug AMX0035 (sodium phenylbutyrate and taurursodiol).

Medical Devices

Radiology Display Device Submission Guidance

FDA publishes a guidance on preparing 510(k) submissions for display devices intended for diagnostic radiology.

latest-news-card-1
Medical Devices

Medical Device Data Systems Guidance

FDA publishes a revised guidance on medical device data systems to conform with the 21st Century Cures Act.

latest-news-card-1
Federal Register

Animal Drug Application Actions Posted

Federal Register notice: FDA amends its animal drug regulations to reflect application-related actions for new animal drug applications and abbreviate...

latest-news-card-1
Federal Register

Meeting on Animal Generic Drug User Fees

Federal Register notice: FDA announces a 10/26 public meeting entitled Animal Generic Drug User Fee Act.

latest-news-card-1
Human Drugs

FDA in New AMP Heart Failure Program

FDA joins with the NIH and other organizations in a new Accelerating Medicines Partnership program on heart failure.

latest-news-card-1
Biologics

Sarepta Submits BLA for Duchenne Gene Therapy

Sarepta Therapeutics files a BLA seeking accelerated approval of SRP-9001 (delandistrogene moxeparvovec) to treat ambulant patients with Duchenne musc...

latest-news-card-1
Human Drugs

Dupixent Gains OK for Prurigo Nodularis

FDA approves Regeneron Pharmaceuticals Dupixent (dupilumab) for treating adult patients with prurigo nodularis. a chronic, inflammatory skin disease.

latest-news-card-1
Human Drugs

Comments on COA Guidance

Four stakeholders suggest ways FDA could improve a draft guidance on fit-for-use clinical outcome assessments.